<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recurrent pregnancy loss is a major health problem effecting 1(see symbol) 2% of women of reproductive age </plain></SENT>
<SENT sid="1" pm="."><plain>Its causes range from chromosomal abnormalities to endocrinological factors and <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> related factors </plain></SENT>
<SENT sid="2" pm="."><plain>Treating <z:hpo ids='HP_0100724'>thrombophilias</z:hpo> especially <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> with low dose aspirin and low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> improves foetal outcome </plain></SENT>
<SENT sid="3" pm="."><plain>This study will add local data to already existing knowledge </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: Sixty selected patients from gynaecology OPD of Aero Hospital with clinical and/or serological findings of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> from February 2009 to January 2011 were given aspirin 75 mg once daily and enoxaparine 40 mg subcutaneously once daily from 6-8 weeks to 35 and 37 weeks respectively </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ninety-three percent of patients achieved live birth </plain></SENT>
<SENT sid="6" pm="."><plain>Out of these 75% patients delivered at term and 18% had preterm delivered </plain></SENT>
<SENT sid="7" pm="."><plain>Four (7%) had early pregnancy loss and only one had early <z:hpo ids='HP_0003811'>neonatal death</z:hpo> due to extreme <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>None of patients experienced any major hemorrhagic complications </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Use of low dose aspirin and low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> is safe in pregnancy and improve foetal outcome in patients with recurrent pregnancy loss due to <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipids syndrome</z:e> </plain></SENT>
</text></document>